Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy
Epilepsy Drug Epidiolex Adds To Sleep, Oncology Franchises
Executive Summary
Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.
You may also be interested in...
UCB's Zogenix Bet Pays Out Quickly With Fresh Fintepla Approval
Gaining approval for Fintepla in Lennox-Gastaut syndrome, on top of an earlier green light in Dravet, puts the Belgian group in a strong position to compete with Jazz’s Epidiolex.
UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy
Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.
Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus
The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.